ATE366324T1 - Inhibierung eines fgf-bindungsproteins durch ribozyme - Google Patents

Inhibierung eines fgf-bindungsproteins durch ribozyme

Info

Publication number
ATE366324T1
ATE366324T1 AT98950713T AT98950713T ATE366324T1 AT E366324 T1 ATE366324 T1 AT E366324T1 AT 98950713 T AT98950713 T AT 98950713T AT 98950713 T AT98950713 T AT 98950713T AT E366324 T1 ATE366324 T1 AT E366324T1
Authority
AT
Austria
Prior art keywords
fgf
ribozymes
binding protein
mrna
found
Prior art date
Application number
AT98950713T
Other languages
English (en)
Inventor
Anton Wellstein
Frank Czubayko
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Application granted granted Critical
Publication of ATE366324T1 publication Critical patent/ATE366324T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT98950713T 1997-09-26 1998-09-25 Inhibierung eines fgf-bindungsproteins durch ribozyme ATE366324T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6017097P 1997-09-26 1997-09-26

Publications (1)

Publication Number Publication Date
ATE366324T1 true ATE366324T1 (de) 2007-07-15

Family

ID=22027820

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98950713T ATE366324T1 (de) 1997-09-26 1998-09-25 Inhibierung eines fgf-bindungsproteins durch ribozyme

Country Status (8)

Country Link
US (1) US6245748B1 (de)
EP (1) EP1034301B1 (de)
JP (1) JP2001517461A (de)
AT (1) ATE366324T1 (de)
AU (1) AU9669498A (de)
CA (1) CA2304987C (de)
DE (1) DE69838035D1 (de)
WO (1) WO1999015703A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene

Also Published As

Publication number Publication date
JP2001517461A (ja) 2001-10-09
CA2304987A1 (en) 1999-04-01
AU9669498A (en) 1999-04-12
WO1999015703A1 (en) 1999-04-01
US6245748B1 (en) 2001-06-12
DE69838035D1 (de) 2007-08-16
CA2304987C (en) 2005-05-17
EP1034301A4 (de) 2005-04-06
EP1034301A1 (de) 2000-09-13
EP1034301B1 (de) 2007-07-04

Similar Documents

Publication Publication Date Title
GB9504265D0 (en) Corticosteroid-containing pharmaceutical composition
ATE338563T1 (de) Verfahren zur behandlung von patienten die unter multipler sklerose leiden mit konsensus- interferon
UA41879C2 (uk) Засіб для лікування мотонейронових захворювань
DK0814831T3 (da) Medikamenter til behandling af autoimmune sygdomme under anvendelse af interferon-tau
DE69315847T2 (de) Verfahren zur behandlung einer durch lfa-1 vermittelten störung
ATA84882A (de) Therapeutisches abgabesystem zur verabreichung eines wirkstoffes durch die haut
DE69502281D1 (de) Verminderung der hautreizung während einer iontophoretischen abgabe von medikamenten
ATE245452T1 (de) Hyaluronatlyase als penetrationsförderer in topischen mitteln
BR9811094A (pt) Agente terapêutico para tumores linfáticos
ATE226014T1 (de) Prophylaktische behandlung der allergischen kontaktdermatitis
DK1407784T3 (da) Antitumormidler
ATE366324T1 (de) Inhibierung eines fgf-bindungsproteins durch ribozyme
DE69533311D1 (de) Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen
EP0423943A3 (en) Use of collagenase inhibitors in the treatment of demyelinating diseases, in particular multiple sclerosis
PT1150703E (pt) Terapia de esclerose multipla com chaperonina 10 e beta-interferao
NO20031650D0 (no) Nye legemidler for leversykdommer
DE60035504D1 (de) Verfahren für die verabreichung von heilmitteln mittels einer dextrinlösung
Nelson et al. Effects of inhibitors of tumor promotion on 12-O-tetradecanoylphor-bol-13-acetate-induced keratin modification in mouse epidermis
BR9608721A (pt) Composição farmacêutica, e, processo para tratar inflamação
Lee et al. AMPHETAMINE INDUCED EXPRESSION OF HSP72 ON PAN-CREAS AND PREVENT AGAINST SECRETAGOGUE INDUCED PANCREATITIS IN RAT.
BG96856U (bg) Лосион за почистване на кожата
BR9105164A (pt) Composto de peptideo,processo para produzir o mesmo,cepa,agente anti-helm intico,aditivo para racao,processo para tratar ou evitar doenca parasitica e processo para melhorar a eficiencia da racao de um animal
HUP9902723A2 (hu) Olanzapin alkalmazása migrénes fájdalom kezelésére szolgáló gyógyszerkészítmény előállítására
MX9605153A (es) Agentes farmaceuticos para el tratamiento de enfermedades inflamatorias cronicas y agudas.
RU98113113A (ru) Способ склерозирования вен при варикозе

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties